Table 5 β-Catenin membranous and nuclear expression in 186 non-lobular invasive breast carcinomas (14/β-catenin clone)

From: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

Parameter	N	Membranous negative	Membranous reduced	Membranous normal	P-value	Nuclear negative	Nuclear positive	P-value
Size—TNM	186				0.534			0.067
T1		9	7	83		92	7
T2		11	9	56		62	14
T3		2	1	8		10	1
Grade	183				0.398			0.043
1		2	1	19		22	0
2		3	3	39		42	3
3		17	13	86		97	19
Type	186				0.342			0.148
IDC		16	15	129		140	20
Mixed		4	2	12		18	0
Other		2	0	6		6	2
LVI	185				0.433			0.322
Negative		8	7	41		47	9
Positive		14	10	105		116	13
LN mets	181				0.304			0.017
Negative		11	6	47		51	13
Positive		11	11	95		108	9
ER	186				0.013			<0.001
Negative		8	6	22		21	15
Positive		14	11	125		143	7
PR	186				0.018			<0.001
Negative		11	6	33		35	15
Positive		11	11	114		129	7
HER2	186				0.029			0.028
Negative		21	11	125		135	22
Positive		1	6	22		29	0
HER2 CISH	176				0.031			0.028
Not amp		21	11	116		127	21
Amp		1	6	21		28	0
EGFR	186				0.200			0.002
Negative		18	14	135		152	15
Positive		4	3	12		12	7
CK14	185				0.019			<0.001
Negative		18	13	137		156	12
Positive		4	4	9		7	10
CK5/6	179				0.214			<0.001
Negative		17	13	128		148	10
Positive		5	2	14		10	11
CK17	184				0.007			<0.001
Negative		16	12	132		147	13
Positive		6	5	13		15	9
Basal CKs	185				0.021			<0.001
Negative		15	12	128		145	10
Positive		7	5	18		18	12
Basal CKs or EGFR	185				0.006			<0.001
Negative		14	11	126		144	7
Positive		8	6	20		19	15
P53	172				0.005			0.005
Negative		10	8	103		112	9
Positive		11	8	32		39	12
MIB-1	171				0.221			<0.001
<10%		5	4	57		61	5
10–30%		10	9	59		71	7
>30%		6	3	18		17	10
Molecular subtype ^a	182				<0.001			<0.001
Basal		7	5	14		13	13
HER2		1	6	23		30	0
Luminal		13	5	108		119	7
Triple-negative	182				0.001			<0.001
No		14	12	130		148	8
Yes		8	5	13		12	14
E-cadherin	166				0.016			0.047
Negative		8	4	16		21	7
Reduced		1	2	10		12	1
Normal		10	10	105		114	11
TOP2A	163				0.566			0.473
Low		7	6	60		66	7
High		13	9	68		77	13
TOP2A CISH	175				0.009			0.223
Not amp		20	12	127		138	21
Amp		1	5	10		16	0
Cyclin D1	173				0.001			<0.001
Low		8	2	9		12	7
Intermediate		3	3	29		28	7
High		10	12	97		112	7
CCND1 CISH	186				0.757			0.320
Not amp		19	14	130		142	21
Amp		3	3	17		22	1
MYC CISH	156				0.710			1,000
Not amp		17	12	111		123	17
Amp		1	2	13		14	2
Caveolin 1	186				0.016			<0.001
Negative		16	15	136		154	13
Positive		6	2	11		10	9
Caveolin 2	164				0.679			<0.001
Negative		18	14	120		139	13
Positive		1	2	9		5	7
Nestin	141				0.026			<0.001
Negative		12	9	102		114	9
Positive		5	3	10		9	9
FOXA1	144				0.001			<0.001
Negative		10	6	22		27	11
Positive		8	7	91		100	6
Bcl2	142				0.048			0.087
Negative		9	8	36		44	9
Positive		7	6	76		83	6

amp: amplified; CISH: chromogenic in situ hybridization; ER: oestrogen receptor; IDC: invasive ductal carcinoma; LN mets: lymph node metastasis; LVI: lympho-vascular invasion; PR: progesterone receptor.
^aMolecular subtypes as defined by Nielsen immunohistochemical surrogate panel.³⁴
Significant P-values are shown in bold.

Back to article page

Table 5 β-Catenin membranous and nuclear expression in 186 non-lobular invasive breast carcinomas (14/β-catenin clone)

Search

Quick links